Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

• Published in: Journal of translational medicine Vol. 9; no. 1; p. 55
• Main Authors: Ido, Akio, Moriuchi, Akihiro, Numata, Masatsugu, Murayama, Toshinori, Teramukai, Satoshi, Marusawa, Hiroyuki, Yamaji, Naohisa, Setoyama, Hitoshi, Kim, Il-Deok, Chiba, Tsutomu, Higuchi, Shuji, Yokode, Masayuki, Fukushima, Masanori, Shimizu, Akira, Tsubouchi, Hirohito
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.05.2011; BioMed Central; BMC
• Subjects: Adult; Aged; Animals; Blood Pressure; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug therapy; Female; Growth factors; Hepatic Encephalopathy - drug therapy; Hepatitis - drug therapy; Hepatitis - physiopathology; Hepatitis B; Hepatocyte Growth Factor - administration & dosage; Hepatocyte Growth Factor - adverse effects; Hepatocyte Growth Factor - pharmacokinetics; Hepatocyte Growth Factor - therapeutic use; Humans; Injections, Intravenous; Kidney - pathology; Liver cells; Male; Middle Aged; Pharmacokinetics; Physiological aspects; Rats; Rats, Wistar; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; Survival Analysis; Swine; Swine, Miniature; Japan
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-9-55

Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule. Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m2/day) intravenously for 12 to 14 days. We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF. Intravenous rh-HGF at a dose of 0.6 mg/m2 was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.